Cargando…

Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns

Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as those affecting DNA methylation, might also ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez-Mut, J V, Heyn, H, Vidal, E, Moran, S, Sayols, S, Delgado-Morales, R, Schultz, M D, Ansoleaga, B, Garcia-Esparcia, P, Pons-Espinal, M, de Lagran, M M, Dopazo, J, Rabano, A, Avila, J, Dierssen, M, Lott, I, Ferrer, I, Ecker, J R, Esteller, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068885/
https://www.ncbi.nlm.nih.gov/pubmed/26784972
http://dx.doi.org/10.1038/tp.2015.214
Descripción
Sumario:Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as those affecting DNA methylation, might also exist. The studied samples were gray matter samples from the prefrontal cortex of control and neurodegenerative disease-associated cases. We performed the DNA methylation analyses of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease and Alzheimer-like neurodegenerative profile associated with Down's syndrome samples. The DNA methylation landscapes obtained show that neurodegenerative diseases share similar aberrant CpG methylation shifts targeting a defined gene set. Our findings suggest that neurodegenerative disorders might have similar pathogenetic mechanisms that subsequently evolve into different clinical entities. The identified aberrant DNA methylation changes can be used as biomarkers of the disorders and as potential new targets for the development of new therapies.